Medication regimen complexity in patients with uncontrolled hypertension and/or diabetes

J Am Pharm Assoc (2003). 2013 Jul-Aug;53(4):427-31. doi: 10.1331/JAPhA.2013.13003.

Abstract

Objectives: To compare medication regimen complexity (MRC) for patients with uncontrolled hypertension, uncontrolled diabetes, or both, to examine the contribution of complexity components (dosage form, frequency, additional directions) to total MRC index (MRCI) score, and to explore the relationship of MRC with patient characteristics and medication regimen cost.

Methods: This cross-sectional retrospective study used electronic medical record data for patients' most recent visit to a university internal medicine clinic during 2009. MRCI scores (disease specific and patient level [medications for all conditions]) were calculated for adults with uncontrolled hypertension, diabetes, or both (i.e., not at recommended treatment goals).

Results: 206 patients (85 with hypertension, 60 with diabetes, and 61 with both) were included. The median (range) disease-specific MRCI was significantly greater for diabetes (8.0 [3-21]) than for hypertension (3.0 [2-11], P < 0.001), though the median number of disease-specific medications was identical (2). The majority of hypertension MRC was the result of dosage frequency (62.1%), while diabetes MRC was distributed among dosage form (38.3%), frequency (39.1%), and additional directions (27.6%). The median patient-level MRCI scores for each group were 11 to 15 points higher than the disease-specific MRCI scores. Higher MRCI scores were associated with higher regimen cost, comorbidity burden, and female gender.

Conclusion: The magnitude of MRCI scores varied across the three disease groups, increased dramatically when all medications were considered, and revealed greater complexity than a simple count of prescribed medications. The MRCI may be a useful tool for targeting patients for whom medication therapy management services would be most beneficial and cost effective.

Publication types

  • Comparative Study
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Antihypertensive Agents / administration & dosage
  • Antihypertensive Agents / economics
  • Antihypertensive Agents / therapeutic use*
  • California / epidemiology
  • Comorbidity
  • Cost-Benefit Analysis
  • Cross-Sectional Studies
  • Diabetes Mellitus / diagnosis
  • Diabetes Mellitus / drug therapy*
  • Diabetes Mellitus / economics
  • Diabetes Mellitus / epidemiology
  • Drug Administration Schedule
  • Drug Costs
  • Drug Therapy, Combination
  • Female
  • Humans
  • Hypertension / diagnosis
  • Hypertension / drug therapy*
  • Hypertension / economics
  • Hypertension / epidemiology
  • Hypoglycemic Agents / administration & dosage
  • Hypoglycemic Agents / economics
  • Hypoglycemic Agents / therapeutic use*
  • Linear Models
  • Male
  • Middle Aged
  • Polypharmacy
  • Retrospective Studies
  • Risk Factors
  • Sex Factors

Substances

  • Antihypertensive Agents
  • Hypoglycemic Agents